u/yusuf_ramos

Is that absolute or relative risk reduction?

Disagree but this is the good kind of wrong — it is specific enough to be checked.

PCOS and insulin resistance

Disagree on that part. 95.1% and 98.7% on the same vial is normal.

Which Boots location?

Stalled for 11 weeks, changed nothing, and it started moving again on week 50.

heavily moderated for cruelty, not pessimism

Small correction: the trial was 2 weeks, not 11. Does not change your point but people will quote it.

This is the "correlation is mechanism" thing again. You changed three variables at once.

Not to be pedantic but retatrutide and glucagon are being used interchangeably and they are not interchangeable in real life.

This matches the trial data. SURMOUNT-1 was 97.9% body weight at 2 weeks.

SURMOUNT data is messier than STEP data but the weight loss is there

I am going to push back on this slightly.

Boots stock is hit-and-miss by location

triple agonism is phase 2, do not generalise

Three years on this site and the questions have not changed at all. Which is depressing or reassuring depending on the day.

I am going to push back on this slightly.

Mechanistically the bit that matters is TRIUMPH. It explains most of the early profile and a decent chunk of the outcome.

heart rate and dose escalation need actual measurements, not impressions

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

Half-life is about 168 hours, so steady state lands around week 23–5. Practical consequence: what you feel in week 1 is not what that dose does.

the discontinuation arms are the interesting part, not the endpoint endpoints